Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities

Abstract

Multiple myeloma (MM) is a biologically heterogeneous malignancy defined by the proliferation of monoclonal plasma cells. Despite the tremendous advancement in MM treatment over the past decades, relapse remains a major problem which is inevitable for most patients. In particular, a partial of patients with early relapse and poor outcomes are classified as a high-risk group. Apart from the clinical stage, genetic aberrations are now recognized as important prognostic factors for identifying high-risk patients. Chromosome 1 abnormalities (C1As), particularly 1q21 gain or amplification, have been identified as common genetic aberrations in patients with MM and are often considered unfavorable prognostic markers for progression-free survival and overall survival. However, more effective therapeutic approaches are still needed to overcome the negative impact of C1As. Therefore, we summarize the prevalence, pathogenesis, clinical significance and present therapeutic condition of C1As in MM, and attempt to conclude the precise and personalized management for patients with C1As.

Keywords:

• Multiple myeloma
• chromosome 1 abnormalities
• molecular pathogenesis
• prognosis
• personalized managements

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This study was funded by the Youth Program of the National Natural Science Foundation of China (No. 82100222) and the Henan Province Medical Science and Technology Tackling Program joint co-construction project, PR China (No.LHGJ20200049).